Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar-based first-line real-world treatment study in non-surgical NSCLC
ChiCTR2400085777Phase 4Not yet recruiting
- Sponsor
- The Peoples' Hospital of Jiaozuo City
- Start
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of endostar in non-small cell lung cancer (NSCLC) (3 arms), sponsored by The Peoples' Hospital of Jiaozuo City. Primary endpoint: Objective response rate. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
endostar
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400085777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085777.